bioRxivCell Biology
Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer
M. MALIER, M. COURT, K. GHARZEDDINE, M. LAVERRIERE, S. MARSILI, F. THOMAS, T. DECAENS, G. ROTH, A. MILLET
Abstract
Colon adenocarcinoma is characterized by an infiltration of tumor-associated macrophages (TAMs). TAMs are associated with a chemoresistance to 5-Fluorouracil (5-FU), but the mechanisms involved are still poorly understood. In the present study, we found that macrophages specifically overexpress dihydropyrimidine dehydrogenase (DPD) in hypoxia, leading to a macrophage-induced chemoresistance to 5-FU by inactivation of the drug. Macrophage DPD expression in hypoxia is translationally controlled by the cap-dependent protein synthesis complex eIF4FHypoxic, which includes HIF-2. We discovered that TAMs constitute the main contributors to DPD activity in human colorectal primary or secondary tumors where cancer cells do not express significant levels of DPD. Together, these findings shed light on the role of TAMs in forming chemoresistance in colorectal cancers and offer the identification of new therapeutic targets. Additionally, we report that, contrary to what is found in humans, macrophages in mice do not express DPD.
- organism: human
- organism: mouse
- assay: proteomics
- assay: metabolomics
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: genetic perturbation / CRISPR
- approach: biophysical modeling
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Metabolic reprogramming of hypoxic tumour-associated macrophages through CSF-1R targeting favours treatment efficiency in colorectal cancers
K. Gharzeddine, C. Gonzales Pietro, … A. MILLET·bioRxiv·Feb 22, 2024
- Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing Thymidine Phosphorylase
Marie Malier, Marie‐Hélène Laverrière, … Arnaud Millet·Cancer LettersPeer-reviewed·Oct 23, 2024
- Macrophage-secreted Pyrimidine Metabolites Confer Chemotherapy Resistance in Acute Myeloid Leukemia (AML)
Chuqi Wang, Yuhan Wang, … Shruti Bhatt·bioRxiv·Nov 1, 2025
- Daily administration of low-dose daunorubicin or doxorubicin inhibits hypoxia-inducible factor 1 and tumor vascularization
Y. Yang, D. Z. Chen, … G. L. Semenza·bioRxiv·Jun 15, 2022
- Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer
C. J. Halbrook, C. Pontious, … C. A. Lyssiotis·bioRxiv·Nov 5, 2018
- An Engineered 3D Co-culture Model of Primary Macrophages and Patient-Derived Tumour Cells to Explore Cellular Responses in the Graded Hypoxic Microenvironment of Pancreatic Cancer
I. L. Co, C. Yu, … A. P. McGuigan·bioRxiv·Jul 13, 2023